Abstract: Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

Abstract: A method for modulating metabolism is provided which includes the step of providing a consumable composition including an extract containing a compound of Formula I to a subject in need thereof thereby modulating the subject's metabolism and addressing the underlying pathogenesis of metabolic disorders, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis and type II diabetes mellitus.

Abstract: Described herein are methods for inhibiting generation of one or more non-classical variant(s) of amyloid precursor protein (APP) gene. Provided herein are methods for diagnosing an individual having or suspected of having Alzheimer's-disease following identification of an expression profile or an activity profile of the one or more non-classical variant(s) and treating the individual using a reverse transcriptase inhibitor or salt thereof.

Abstract: A print consumable may include a rotatable core, a roll of dispensable print substrate, and a radio-frequency identification (RFID) tag. The roll of the dispensable print substrate may be dispensably secured to the core. The RFID tag may be secured to the core and configured to rotate about a core axis. The RFID tag includes an RFID antenna coupled to an RFID chip. The RFID chip may include a print counter, a stock-keeping unit (SKU) code, and a consumable authentication code. A print system may include a housing, a holder to hold the print consumable, a print head, a transceiver, a trace antenna for reading an RFID tag of the print consumable, and a controller. The controller may be configured to receive a signal from the transceiver indicative of one or more of the print counter, the SKU code, and the consumable authentication code received from the RFID antenna.

Abstract: The present invention relates to a novel fused ring compound having urea structure that exhibits excellent NAMPT activating effect, and a method using the same for treating/preventing metabolic disorder, cardiovascular and kidney disease, mitochondrial disease, neurodegenerative disease, ocular disease, and muscle wasting disorder. The present invention provides a compound represented by following formula (I) or a pharmacologically acceptable salt: wherein A, B, R1, R2 and R3 represent the same meanings as in the claims.

Abstract: The present disclosure provides an apparatus including: (a) a frame having a first end and a second end, wherein the frame includes a plurality of struts arranged between the first end and the second end of the frame, (b) a plurality of channels disposed within the plurality of struts of the frame, (c) an infusion balloon coupled to the frame and arranged such that, in an expanded condition, the frame provides a plurality of openings that the infusion balloon is configured to expand through and extend radially outward from the frame, thereby defining a plurality of grooves, (d) a plurality of holes defined in the frame and configured to permit fluid communication between the plurality of channels and the plurality of grooves, and (e) an infusion hub arranged at the first end or the second end of the frame including a reservoir in fluid communication with the plurality of channels.

Abstract: Disclosed herein are methods of inhibiting nuclear pore complex assembly and inducing nuclear pore complex disassembly. Methods to screen for agents that inhibit nuclear pore assembly or induce nuclear pore complex disassembly are also disclosed.

Abstract: Described are platforms, systems, and methods for screening patients. In one aspect, a computer-implemented method comprises: receiving, from a cellular imaging device, image data comprising calcium kinetic features of neuronal cultures derived from a patient; processing the image data through a machine-learning model to determine a diagnosis for the patient based on the calcium kinetic features, the machine-learning model trained using neuronal calcium data; and providing the diagnosis a user interface.

Abstract: High opacity permanent ink formulations comprising a solvent, a polymer-based opacifier, a coloring agent, a resin, and a humectant, wherein the ink formulation displays a viscosity of less than about 50 cP, are provided herein.

Abstract: Reverse photochromic ink formulations containing at least one reverse photochromic colorant, methods of erasing reverse photochromic ink formulations by exposing them to UV light, and writing instruments including a writing tip portion connected to a light-shielding tubular member or refill and a reverse photochromic ink formulation are provided herein.

Abstract: A visceral double-barreled main body stent graft and methods for its use, the stent graft comprises, a main body stent graft having distal and proximal ends, the main body stent graft's length ranges from about 100-120 mm and diameter at the proximal end ranges from about 30-45 mm, first and second lumens defined at the main body stent graft's distal end, the first lumen's diameter ranges from about 18-20 mm, the second lumen's diameter ranges from about 16-18 mm, the first and second lumens have about the same length from about 50-70 mm, the first lumen is secured to the second lumen along a shared length, and the main body stent graft defines a tubular wall that is contiguous with the first and second lumens such that any fluid entering the main body must exit through one of the first or second lumens.

Abstract: Disclosed are peptides and peptidomimetics that in some embodiments include the amino acid sequence KRGARST or (SEQ ID NO: 1), AKRGARSTA or (SEQ ID NO: 2), or CKRGARSTC (SEQ ID NO: 3).

Abstract: Spinnable packages and package assemblies for products are provided. Spinnable packages include a base having a plate with a top surface and an opposed bottom surface, and a protrusion extending from the top surface of the plate. The packages also include a wheel configured to removably secure a plurality of products, the wheel having an aperture extending therethrough, wherein the wheel and the base are sized and shaped such that the wheel is spinnably mountable on the base when the protrusion is positioned in the aperture, such that the wheel is spinnable about a longitudinal axis of the protrusion.

Abstract: Reverse photochromic ink formulations containing encapsulated reverse photochromic colorant, methods of erasing reverse photochromic ink formulations including encapsulated reverse photochromic colorants by exposing them to UV light, and writing instruments including a writing tip portion connected to a light-shielding tubular member or refill and a reverse photochromic ink formulation including encapsulated reverse photochromic colorant are provided herein.

Abstract: Writing instruments with flexible nibs for reduced writing force in use are provided. A nib includes a nib body having a flexible upper writing portion and a lower portion in communication with the flexible upper writing portion, the lower portion of the nib body being configured to deliver ink to the flexible upper writing portion and the flexible upper writing portion being configured to deliver ink to a writing surface, wherein the flexible upper writing portion of the nib body has a flattened chisel-shaped tip at a superior end of the flexible upper writing portion, and wherein the nib is effective to deliver ink to the writing surface upon application of a force of less than about 0.1 lbs thereto.

Abstract: Methods of determining a disease score of a patient diagnosed with lysosomal storage disease (LSD) are described. The disease score includes one or more of the following: (i) one or more biofluid biomarkers; (ii) one or more neurophysiological measurements; and (iii) one or more neurobehavior measurement. Also described method of treating LSD including determining the disease score and administering to the patient a therapy. The therapy includes one or more of the following: (i) enzyme replacement therapy, (ii) gene therapy; and (iii) a small molecule.

Abstract: Compositions for use in writing instruments that provide for an opaque and permanent application and include a unique combination of a hollow particle component, a colorant, a viscosity modifier, a humectant, and an optional dispersant that result in shear-thinning properties.